Researchers building inflammation protocol panels will find that GHK-Cus NF-kB mechanism is distinct from corticosteroid-based or COX inhibitor-based approaches, with a more selective and tissue-repair-compatible effect profile
Unlike traditional GLP-1 receptor agonists such as semaglutide, it targets three key metabolic pathwaysthe GLP-1, GIP, and glucagon receptorsthat regulate appetite, energy expenditure, and blood sugar levels
Backed by preclinical and clinical studies with human relevance
With the expert guidance of Rosaly Stephens, ARNP-C, we make sure every patient feels both physically and mentally prepared for their first dose, laying the foundation for a transformation that is not only effective but also comfortable
The FDA offers specific location guidance for these three injection sites